



KAZIA
THERAPEUTICS



A company developing
innovative, high-impact
drugs for cancer

Presentation to Bell Potter
Healthcare Conference

Dr James Garner
Chief Executive Officer & Managing Director

26 November 2020

Forward-Looking Statements

This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of customer acceptance of existing and new products and services and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to sales, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, marketing existing products and services update the forward-looking information contained in this presentation.

Investment Rationale

World-Class Asset in Brain Cancer

- Paxalisib developed by Genentech, the world's most successful cancer drug company
- Well-proven mechanism of action, with unique differentiating factor of brain penetration
- Strong scientific rationale for development in brain cancer
- Encouraging clinical data emerging from US -based phase II study
- Potential best-in-class toxicity profile


Clear Path to Commercialisation

- FDA-endorsed GBM AGILE study will serve as pivotal study for registration
- US\$ 1.5 billion pa commercial opportunity in glioblastoma, with potential upside in other cancers
- High unmet medical need – existing standard of care ineffective in two -thirds of patients
- 5x additional clinical studies at top tier US hospitals provide multiple shots on goal
- Optimised regulatory position with Orphan, Fast Track, and Rare Paediatric Disease Designations

Strong Corporate Story

- Kazia is a late-clinical-stage company, funded for phase III, with one of the leading assets in the global glioblastoma pipeline, and the potential to address a \$1.5 billion market
- Highly-efficient operating model, with ~80% of expenditure applied directly to R&D
- Lean team of internationally -experienced drug developers
- Good potential for partnering and / or M&A during remaining development of paxalisib

Latest phase II data compares well to historical data for temozolomide (existing standard of care)



Note: figures for existing therapy are for temozolomide, per Hegi et al. (2005); comparison between different studies is never perfectly like-for-like

GBM AGILE is the planned pivotal study for paxalisib in glioblastoma

What is GBM AGILE?

- A 'platform study', designed by the leading experts in brain cancer to expedite the approval of new drugs for glioblastoma
- Multiple drugs can be evaluated in parallel, saving time and money; Bayer's Stivarga (regorafenib) is the first drug to participate, and Kazia's paxalisib will be the second
- FDA has provided strong endorsement, saying that positive data from GBM AGILE will be suitable for product registration
- The study is currently active at approximately 28 hospitals in the United States and Canada and recruiting very well; expansion to Europe and China is expected in 1H CY2021
- Cutting-edge 'adaptive design' ensures that the study will only recruit the number of patients needed to reach an answer (up to 200 on paxalisib), avoiding redundancy and ensuring the fastest possible path to market

Who is Behind It?

GBM AGILE is sponsored by the Global Coalition for Adaptive Research (GCAR), a not-for-profit entity based in the United States

The study's scientific leadership includes world-leading experts in glioblastoma, among them several clinicians who have participated in clinical trials of paxalisib

GBM AGILE has received substantial grant funding, substantially reducing the cost of participation for companies such as Kazia

A broad-based clinical program is underway across multiple forms of brain cancer

Paxalisib (GDC-0084)

Primary Brain Cancer (brain cancer that begins in the brain)

Secondary Brain Cancer (brain cancer that spreads from elsewhere in the body)

Glioblastoma

Most common and most aggressive brain tumour

Phase II

[NCT03522298](https://clinicaltrials.gov/ct2/show/study/NCT03522298)



Glioblastoma

(planned pivotal study for approval [in set-up])

Phase II / III

[NCT03970447](https://clinicaltrials.gov/ct2/show/study/NCT03970447)



DIPG

Highly aggressive childhood brain tumour

Phase I

[NCT03696355](https://clinicaltrials.gov/ct2/show/study/NCT03696355)



Primary CNS Lymphoma

Treatment-resistant brain cancer

Phase II

TBD



Brain Metastases

Cancer that has spread from any primary tumour

Phase II

[NCT03994796](https://clinicaltrials.gov/ct2/show/study/NCT03994796)



Breast Cancer Brain Mets

(combination with Herceptin®)

Phase II

[NCT03765983](https://clinicaltrials.gov/ct2/show/study/NCT03765983)



Brain Metastases

(combination with radiotherapy)

Phase I

[NCT04192981](https://clinicaltrials.gov/ct2/show/study/NCT04192981)



Funded by Kazia

Funded Primarily Through Partnerships and External Funding

Positive newsflow has supported revaluation of Kazia as paxalisib moves towards commercialisation



Market Capitalisation	~AU\$ 100 million										
Shares on Issue	~126 million										
Listing	ASX: KZA NASDAQ: KZIA (1:10 ratio)										
Key Shareholders	<table border="0"> <tbody> <tr> <td>Willoughby Capital</td> <td>16%</td> </tr> <tr> <td>Platinum Asset Mgmt.</td> <td>9%</td> </tr> <tr> <td>Quest Asset Partners</td> <td>9%</td> </tr> <tr> <td>UniSuper</td> <td>6%</td> </tr> <tr> <td>Board & Mgmt.</td> <td>2%</td> </tr> </tbody> </table>	Willoughby Capital	16%	Platinum Asset Mgmt.	9%	Quest Asset Partners	9%	UniSuper	6%	Board & Mgmt.	2%
Willoughby Capital	16%										
Platinum Asset Mgmt.	9%										
Quest Asset Partners	9%										
UniSuper	6%										
Board & Mgmt.	2%										
Balance Sheet (as at 30 Sept 20)	<table border="0"> <tbody> <tr> <td>Cash:</td> <td>\$6.5 million</td> </tr> <tr> <td>FY20 Spend:</td> <td>\$12.5 million</td> </tr> <tr> <td>Runway:</td> <td>2Q CY2021</td> </tr> <tr> <td>Efficiency:</td> <td>~80% R&D</td> </tr> </tbody> </table>	Cash:	\$6.5 million	FY20 Spend:	\$12.5 million	Runway:	2Q CY2021	Efficiency:	~80% R&D		
Cash:	\$6.5 million										
FY20 Spend:	\$12.5 million										
Runway:	2Q CY2021										
Efficiency:	~80% R&D										


Note: AU\$ 25 million financing completed in October 2020

Note: as at 30 October 2020, unless otherwise noted

Key Milestones and Anticipated Newsflow

Execution of definitive agreement with GCAR for GBM AGILE pivotal study	October 2020	✓
Further interim data from Kazia phase II glioblastoma trial	November 2020	✓
Initial interim data from phase I DIPG trial at St Jude	November 2020	✓
Initial interim data from phase II BCBM trial at Dana -Farber	Q4 CY2020	
Commencement of recruitment to GBM AGILE pivotal study in glioblastoma	Q4 CY2020	
Commencement of recruitment to phase II PCNSL study at Dana -Farber	Q1 CY2021	
Half-Year Report	Q1 CY2021	
Initial interim data from phase II brain mets study by Alliance Group	H1 CY2021	
Initial interim data from phase I brain mets study at Sloan-Kettering	H1 CY2021	
Final data from Kazia phase II glioblastoma trial	H1 CY2021	

Note: all guidance is indicative, and subject to amendment in light of changing conference schedules, operational considerations, etc.



KAZIA
THERAPEUTICS

www.kaziatherapeutics.com